(Adnkronos) – Maurizio Rossini, full professor of rheumatology at the University of Verona and director of the rheumatology operating unit of the integrated university hospital of Verona, present at the press conference announcing the reimbursement of romosozumab, the new drug for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture, developed by UCB in collaboration with Amgen, illustrates the mechanism of action of the new drug.
#Fragility #fractures #Rossini #Romosozumab #leads #improvements #months
Raynaud’s phenomenon, what causes it and how is it treated?
Raynaud's phenomenon is a peripheral circulation disorder: it lasts on average 20-30 minutes and the skin becomes white and then...
